Nectin Therapeutics
PrivateLast Round
VC Round
May 6, 2024
Total Funding Raised
$11.4M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Nectin Therapeutics operates in Healthcare & Life Sciences and is based in Jerusalem. Its latest recorded funding round was a VC Round in May 2024.
Nectin Therapeutics is a biotechnology company that develops next-generation immuno-oncology therapies and antibody-drug conjugates to treat solid and hematological malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Nectin Therapeutics Comparables
Compare Nectin Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| GSK plc | 73% | |
| iTeos Therapeutics | 73% | |
| Compugen Ltd. | 71% |
For institutional investors. Book with your work email.
Nectin Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | May 6, 2024 | ||||
| VC Round | May 16, 2023 | ||||
| Grant | Nov 30, 2022 | ||||
| VC Round | Mar 7, 2022 | ||||
| Series A | Jul 14, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Nectin Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Israel Biotech Fund | VC Round, Grant |
| Peregrine Ventures (California) | Grant |
| The University of Texas MD Anderson Cancer Center | Grant |
| Integra Holdings | Series A, VC Round, Grant |
| aMoon | Grant |
| Cancer Focus Fund | VC Round, Grant |
| Guangzhou Sino-Israel Bio-Industry Investment Fund | VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 13, 2026
Monthly visitors increased 31% MoM.
- Aug 20, 2026
Monthly visitors increased 68% MoM, reaching 2.4K.
For institutional investors. Book with your work email.
Nectin Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Nectin Therapeutics's valuation, stock price, and market status.
Is Nectin Therapeutics a public or private company?
Nectin Therapeutics is a private company.
What is the current stock price of Nectin Therapeutics?
Nectin Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nectin Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Nectin Therapeutics worth (valuation)?
Valuation information for Nectin Therapeutics is not publicly available.
Can I buy Nectin Therapeutics stock?
Nectin Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Nectin Therapeutics's last funding round?
Nectin Therapeutics's most recent funding round was VC Round on May 6, 2024.
Who are the main investors in Nectin Therapeutics?
Key investors in Nectin Therapeutics include Israel Biotech Fund, Cancer Focus Fund.
Will Nectin Therapeutics IPO soon?
No public IPO plans have been announced for Nectin Therapeutics.
How can I track Nectin Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Nectin Therapeutics's shares on secondary markets.